[go: up one dir, main page]

DE122005000030I2 - Pregna-1,4-dien-3,20-dion-16-17-acetal-21-ester, Verfahren zur Herstellung, sowie diese enthaltende pharmazeutische Präparate - Google Patents

Pregna-1,4-dien-3,20-dion-16-17-acetal-21-ester, Verfahren zur Herstellung, sowie diese enthaltende pharmazeutische Präparate

Info

Publication number
DE122005000030I2
DE122005000030I2 DE200512000030 DE122005000030C DE122005000030I2 DE 122005000030 I2 DE122005000030 I2 DE 122005000030I2 DE 200512000030 DE200512000030 DE 200512000030 DE 122005000030 C DE122005000030 C DE 122005000030C DE 122005000030 I2 DE122005000030 I2 DE 122005000030I2
Authority
DE
Germany
Prior art keywords
pregna
dione
acetal
diene
esters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE200512000030
Other languages
English (en)
Other versions
DE122005000030I1 (de
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Altana Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma AG filed Critical Altana Pharma AG
Publication of DE122005000030I1 publication Critical patent/DE122005000030I1/de
Publication of DE122005000030I2 publication Critical patent/DE122005000030I2/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0092—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by an OH group free esterified or etherified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE200512000030 1990-09-07 1991-09-05 Pregna-1,4-dien-3,20-dion-16-17-acetal-21-ester, Verfahren zur Herstellung, sowie diese enthaltende pharmazeutische Präparate Active DE122005000030I2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57894290A 1990-09-07 1990-09-07

Publications (2)

Publication Number Publication Date
DE122005000030I1 DE122005000030I1 (de) 2005-10-06
DE122005000030I2 true DE122005000030I2 (de) 2007-12-06

Family

ID=24314964

Family Applications (2)

Application Number Title Priority Date Filing Date
DE200512000030 Active DE122005000030I2 (de) 1990-09-07 1991-09-05 Pregna-1,4-dien-3,20-dion-16-17-acetal-21-ester, Verfahren zur Herstellung, sowie diese enthaltende pharmazeutische Präparate
DE4129535A Expired - Lifetime DE4129535C2 (de) 1990-09-07 1991-09-05 Pregna-1,4-dien-3,20-dion-16-17-acetal-21-ester, Verfahren zur Herstellung, sowie diese enthaltende pharmazeutische Präparate

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE4129535A Expired - Lifetime DE4129535C2 (de) 1990-09-07 1991-09-05 Pregna-1,4-dien-3,20-dion-16-17-acetal-21-ester, Verfahren zur Herstellung, sowie diese enthaltende pharmazeutische Präparate

Country Status (18)

Country Link
US (1) US5482934A (de)
JP (1) JP3292928B2 (de)
KR (1) KR100193085B1 (de)
AT (1) AT402930B (de)
AU (1) AU649472B2 (de)
BE (1) BE1005876A5 (de)
BR (1) BR1100860A (de)
CA (1) CA2050812C (de)
CH (1) CH683343A5 (de)
DE (2) DE122005000030I2 (de)
ES (1) ES2034893B1 (de)
FR (1) FR2666585B1 (de)
GB (1) GB2247680B (de)
GR (1) GR1001529B (de)
IT (1) IT1251376B (de)
LU (2) LU88001A1 (de)
NL (2) NL194917C (de)
PT (1) PT98897B (de)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU213221B (en) 1990-03-02 1997-03-28 Glaxo Group Ltd Inhalation device and medicine packet for device
UA26230A (uk) 1990-03-02 1999-07-19 Глексо Груп Лімітед Іhгалятор для спільhого використаhhя з лікувальhим блоком і лікувальhий блок
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
WO1994022899A1 (de) * 1993-04-02 1994-10-13 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue prednisolonderivate
DE59508898D1 (de) * 1994-03-09 2001-01-18 Byk Gulden Lomberg Chem Fab Neue silylverbindungen und ihre verwendung
DE19635498A1 (de) 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
SE9604751D0 (sv) * 1996-12-20 1996-12-20 Astra Ab New therapy
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
US6264923B1 (en) 1998-05-13 2001-07-24 3M Innovative Properties Company Medicinal aerosol formulation of ciclesonide and related compounds
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
DE10055820C1 (de) * 2000-11-10 2002-07-25 Byk Gulden Lomberg Chem Fab Verfahren zur Herstellung eines Glucocorticoids
CA2430196C (en) 2000-11-10 2010-01-26 Altana Pharma Ag Process for the production of 16,17-[(cyclohexylmethylen)bis(oxy)]-11,21-dihydroxy-pregna-1,4-dien-3,20-dion or its 21-isobutyrat by transketalisation
ITMI20020148A1 (it) * 2002-01-29 2003-07-29 Nicox Sa Nuovi corticosteroidi
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
JP4746318B2 (ja) * 2002-08-30 2011-08-10 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング シクレソニドと抗ヒスタミン剤との組合せ物を含有するアレルギー性鼻炎の治療用医薬組成物
WO2004033478A2 (en) * 2002-10-08 2004-04-22 Sepracor Inc. Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory
US7879833B2 (en) 2002-12-12 2011-02-01 Nycomed Gmbh Combination medicament
CN100404545C (zh) * 2003-03-27 2008-07-23 尼科梅德有限责任公司 具有规定粒径的结晶环缩松的制备方法
MY143936A (en) 2003-03-27 2011-07-29 Nycomed Gmbh Process for preparing crystalline ciclesonide with defined particle size
GB0312148D0 (en) * 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
EP1635845A1 (de) 2003-06-13 2006-03-22 ALTANA Pharma AG Kombination aus formoterol und ciclesonid
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
US7825147B2 (en) * 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
WO2005025577A1 (en) * 2003-09-15 2005-03-24 Altana Pharma Ag Use of ciclesonide for the treatment of inflammatory bowel diseases
WO2005025578A1 (en) * 2003-09-16 2005-03-24 Altana Pharma Ag Use of ciclesonide for the treatment of respiratory diseases
EP1694655A2 (de) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Phosphodiesteraseinhibitoren
PE20050941A1 (es) 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
CA2563556C (en) * 2004-04-20 2013-01-29 Altana Pharma Ag Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
CN100338089C (zh) * 2004-08-12 2007-09-19 重庆医药工业研究院有限责任公司 一种哮喘病治疗药物环索奈德的新的制备方法
US20080027034A1 (en) * 2004-09-10 2008-01-31 Shah Tushar P Ciclesonide and Syk Inhibitor Combination and Method of Use Thereof
CN100345864C (zh) * 2004-10-29 2007-10-31 天津药业研究院有限公司 一种治疗呼吸道疾病的甾体药物的制备方法及其中间体
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
WO2006138212A1 (en) * 2005-06-14 2006-12-28 Gilead Sciences, Inc. SUBSTITUTED PHENYLPHOSPHATES AS MUTUAL PRODRUGS OF STEROIDS AND β -AGONISTS FOR THE TREATMENT OF PULMONARY INFLAMMATION AND BRONCHOCONSTRICTION
CN1325508C (zh) * 2005-06-21 2007-07-11 浙江仙琚制药股份有限公司 一锅法制备泼尼松龙衍生物
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
US20080221073A1 (en) * 2005-09-02 2008-09-11 Francesca Benedini Nitrooxy Derivatives of Glucocorticoids
EP1934219A1 (de) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituierte pyrazolo-[3,4-b]-pyridine als phosphodiesterase-inhibitoren
WO2007045979A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
US20090054382A1 (en) * 2005-10-19 2009-02-26 Abhijit Ray Compositions of phosphodiesterase type iv inhibitors
US20070135398A1 (en) * 2005-11-02 2007-06-14 Pierluigi Rossetto Process for the preparation of ciclesonide
WO2007092574A2 (en) * 2006-02-08 2007-08-16 Sicor, Inc. Crystalline forms of ciclesonide
US20070232578A1 (en) * 2006-02-15 2007-10-04 Pierluigi Rossetto Crystalline forms of ciclesonide
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
WO2008015696A2 (en) * 2006-05-23 2008-02-07 Cadila Healthcare Limited Process for preparing ciclesonide
CN101553493B (zh) 2006-07-19 2012-07-04 阿斯利康(瑞典)有限公司 三环螺哌啶化合物、它们的合成和它们作为趋化因子受体活性调节剂的用途
JP5399902B2 (ja) 2006-08-22 2014-01-29 ランバクシー ラボラトリーズ リミテッド マトリックスメタロプロテイナーゼ阻害剤
WO2008062450A2 (en) * 2006-09-18 2008-05-29 Cadila Healthcare Limited Crystalline polymorphs of ciclesonide
NZ575549A (en) * 2006-09-19 2012-06-29 Cipla Ltd Processes for the preparation of ciclesonide and its crystal form
BRPI0717058A2 (pt) * 2006-09-22 2013-10-15 Ranbaxy Lab Ltd Composto, composição farmacêutica, método para tratar, prevenir, inibir ou suprimir uma condição inflamatória ou doença ou doenças do sistema nervoso central e método para a preparação de um composto
EP2066661A2 (de) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesteraseinhibitoren
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
RU2009120229A (ru) 2006-12-19 2011-01-27 Астразенека Аб (Se) Производные хинуклидинола в качестве антагонистов мускариновых рецепторов
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
EP2124943A1 (de) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridinderivate als phosphodiesterasehemmer
NZ579645A (en) 2007-03-14 2012-01-12 Ranbaxy Lab Ltd Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
EP2022796A1 (de) * 2007-08-07 2009-02-11 Nycomed GmbH Amorphes Ciclesonid
US20090075959A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched ciclesonide
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (de) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. 4-(2-Amino-1-hydroxyethyl)Phenol-Derivate als Agonisten des b2-adrenergen Rezeptors
ES2401057T3 (es) * 2008-03-13 2013-04-16 Farmabios S.P.A. Procedimiento para la preparación de derivados de pregnano
EP2111861A1 (de) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Zusammensetzungen von Phosphodiesterase-IV-Hemmern
BRPI0822693A2 (pt) 2008-05-13 2015-07-07 Astrazeneca Ab Derivados de quinuclidina como antagonistas do receptor muscarínico m3
AU2009247021B2 (en) * 2008-05-13 2012-06-07 Astrazeneca Ab Pharmaceutical product comprising a muscarinic receptor antagonist and a beta2-adrenoceptor agonist
EP2297106B1 (de) 2008-05-27 2014-07-16 AstraZeneca AB Phenoxypyridinylamidderivate und ihre verwendung zur behandlung von pde4-vermittelten krankheitszuständen
US20100120737A1 (en) * 2008-11-10 2010-05-13 Martin Feth Amorphous ciclesonide
WO2010067102A1 (en) 2008-12-09 2010-06-17 Astrazeneca Ab Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
WO2010104187A1 (ja) 2009-03-09 2010-09-16 三笠製薬株式会社 ステロイド化合物
EP2228368A1 (de) 2009-03-12 2010-09-15 Almirall, S.A. Verfahren zur Herstellung von 5-(2-{[6-(2,2-Difluor-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxychinolin-2(1H)-on
CA2776164C (en) 2009-10-01 2016-12-13 Aptalis Pharmatech, Inc. Orally administered corticosteroid compositions
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
CA2785468A1 (en) * 2009-12-23 2011-06-30 Psivida Us, Inc. Sustained release delivery devices
WO2011093814A2 (en) 2010-01-29 2011-08-04 Mahmut Bilgic A pharmaceutical combination comprising formoterol and ciclesonide
WO2011136752A1 (en) 2010-04-26 2011-11-03 Mahmut Bilgic Combined pharmaceutical composition comprising carmoterol and ciclesonide for the treatment of respiratory diseases
CN102477064B (zh) * 2010-11-23 2014-06-11 天津金耀集团有限公司 一种制备环索奈德的16,17缩酮中间体
MX2014001940A (es) 2011-08-18 2014-03-27 Takeda Gmbh Producto farmaceutico de aerosol para administracion por inhalacion oral o nasal.
EP2578570A1 (de) 2011-10-07 2013-04-10 Almirall, S.A. Neues Verfahren zur Herstellung von 5-(2-{[6-(2,2-Difluor-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxychinolin-2(1H)-on mittels neuen Synthesezwischenstoffen
WO2013109212A1 (en) 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising ciclesonide
US9109005B2 (en) 2012-02-23 2015-08-18 Boehringer Ingelheim International Gmbh Method for manufacturing of ciclesonide
EP2641900A1 (de) 2012-03-20 2013-09-25 Almirall, S.A. Neuartige polymorphe Kristallformen von 5-(2-{[6-(2,2-difluor-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxychinolin-2(1H)-on, Heminapadisylat als Agonist des beta2-adrenergen Rezeptors
US20150224197A1 (en) 2012-07-05 2015-08-13 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation compositions
WO2014007770A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising corticosteroid and sorbitol
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
EP3250211B1 (de) 2015-01-30 2021-12-22 Coral Drugs Pvt. Ltd. Neuartiges verfahren zur herstellung von glucocorticoidsteroiden
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CN106749493A (zh) * 2017-01-09 2017-05-31 河南利华制药有限公司 一种哈西奈德中间体的制备工艺
US11756656B2 (en) 2018-06-14 2023-09-12 Astrazeneca Uk Limited Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
KR20250069711A (ko) * 2022-07-21 2025-05-19 파이어플라이 바이오, 인크. 글루코코르티코이드 수용체 작용제 및 이의 접합체
WO2025085662A1 (en) 2023-10-17 2025-04-24 Vanderbilt University Compounds for tocolytic use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3079384A (en) * 1960-10-10 1963-02-26 Olin Mathieson C-ring substituted 6alpha-halo steroids and process for producing them
SE378109B (de) * 1972-05-19 1975-08-18 Bofors Ab
US3992534A (en) * 1972-05-19 1976-11-16 Ab Bofors Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods
SE378110B (de) * 1972-05-19 1975-08-18 Bofors Ab
CH608244A5 (en) * 1974-02-27 1978-12-29 Pierrel Spa Process for the preparation of steroids
US4272446A (en) * 1974-02-27 1981-06-09 Pierrel S.P.A. Steroids and process for preparing the same
GB1504294A (en) * 1974-03-05 1978-03-15 Palladino G 6 beta-fluoropregnane compounds
NL7412537A (nl) * 1974-05-17 1975-11-19 Lark Spa Werkwijze voor het bereiden van 16.17-cyclische acetalen en ketalen van 9-(alpha)-halogeensteroiden.
US4036831A (en) * 1975-10-28 1977-07-19 Steroid Development Company Establishment Trimethyl siloxane steroid intermediates
DE3012888A1 (de) * 1980-03-31 1981-10-08 Schering Ag Berlin Und Bergkamen, 1000 Berlin Neue steroide und verfahren zu ihrer herstellung
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
DE3640709A1 (de) * 1986-11-28 1988-06-09 Schering Ag Verfahren zur herstellung von 6(alpha),9(alpha)-difluor-11ss,17(alpha)-dihydroxy-16(alpha)-methyl-4-pregnen-3,20-dion und dessen derivate

Also Published As

Publication number Publication date
CA2050812A1 (en) 1992-03-08
PT98897A (pt) 1992-07-31
ATA176991A (de) 1997-02-15
LU91205I2 (fr) 2006-05-30
AU649472B2 (en) 1994-05-26
FR2666585A1 (fr) 1992-03-13
ES2034893A1 (es) 1993-04-01
NL300196I1 (nl) 2005-08-01
GR1001529B (el) 1994-03-31
ITMI912296A1 (it) 1993-02-28
IT1251376B (it) 1995-05-09
GB9118967D0 (en) 1991-10-23
BE1005876A5 (nl) 1994-02-22
LU88001A1 (fr) 1992-06-01
CA2050812C (en) 2003-07-29
NL194917C (nl) 2003-09-01
DE4129535C2 (de) 2001-03-15
PT98897B (pt) 2000-10-31
HK1005881A1 (en) 1999-01-29
ITMI912296A0 (it) 1991-08-28
DE122005000030I1 (de) 2005-10-06
DE4129535A1 (de) 1992-03-12
GR910100353A (en) 1992-09-11
US5482934A (en) 1996-01-09
NL300196I2 (nl) 2005-10-03
KR100193085B1 (ko) 1999-06-15
GB2247680B (en) 1994-06-01
KR920006365A (ko) 1992-04-27
JP3292928B2 (ja) 2002-06-17
BR1100860A (pt) 1999-08-31
ES2034893B1 (es) 1994-01-01
NL9101472A (nl) 1992-04-01
AT402930B (de) 1997-09-25
GB2247680A (en) 1992-03-11
AU8368691A (en) 1992-03-12
JPH04257599A (ja) 1992-09-11
CH683343A5 (de) 1994-02-28
FR2666585B1 (fr) 1994-09-09

Similar Documents

Publication Publication Date Title
DE122005000030I2 (de) Pregna-1,4-dien-3,20-dion-16-17-acetal-21-ester, Verfahren zur Herstellung, sowie diese enthaltende pharmazeutische Präparate
DE3485075D1 (de) Pharmazeutische zubereitung zur heilung der erkrankungen der zahnwurzelhaut und verfahren zu deren herstellung.
DE69327659D1 (de) Therapeutische und diagnostische bilderzeugungzusammensetzung und verfahren zur herstellung
ATA162587A (de) Verfahren zur herstellung von neuen benzolderivaten sowie von diese derivate enthaltenden pharmazeutischen zusammensetzungen und verfahren zur verringerung von entzündung bei tieren
ATA125988A (de) Pharmazeutische cefuroximaxetil-zusammensetzung und verfahren zu ihrer herstellung
ATE187167T1 (de) Amido-3-pyrazol-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
DE69634613D1 (de) Neue stabilisierte galenische Formulierungen enthaltend ein säureempfindliches Benzimidazol und Verfahren zu ihrer Herstellung
ATE231882T1 (de) 7alpha-(epsilon-aminoalkyl)-estratriene, verfahren zu deren herstellung, pharmazeutische präparate, die diese 7alpha-(epsilon-aminoalkyl)- estratriene enthalten sowie deren verwendung zur herstellung von arzneimitteln
ATE82495T1 (de) Verfahren zur herstellung pharmazeutischer mischungen.
DE69411604D1 (de) Wirkstoffzusammensetzung und Verfahren zu ihrer Herstellung
DE69126076D1 (de) Verbundswafer und Verfahren zu dessen Herstellung
DE59310166D1 (de) Cyclosporin(e) enthaltende pharmazeutische Zubereitung zur intravenösen Applikation sowie Verfahren zu ihrer Herstellung
ATA195788A (de) Tripeptide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATA900894A (de) Pharmazeutische kompositionen zum vorbeugen und heilen von krebserkrankungen und verfahren zu ihrer herstellung
DE69924846D1 (de) Thyroidhormon-analoga und verfahren zu ihrer herstellung
PT86331A (de) Neue pyrrolobenzimidazole verfahren zu ihrer herstellung sowie arzneimittel
DE59608606D1 (de) Cyclosprorin(e) enthaltende pharmazeutische zubereitung zur oralen applikation und verfahren zu ihrer herstellung
DE69610036D1 (de) Pyridazinone-Derivate und Verfahren zur deren Herstellung
DE3682811D1 (de) Pharmazeutische zusammensetzung zur heilung und verhuetung kardiovaskularer krankheiten und verfahren zu ihrer herstellung.
DE69028602D1 (de) Pyridazin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
ATA903983A (de) Verfahren zur herstellung einer analgetischen und antiinflammatorischen pharmazeutischen zubereitung
DE69608490D1 (de) Maltitol Zusammensetzung und Verfahren zu ihrer Herstellung
DE69012650D1 (de) Piperidinderivat, Verfahren zur Herstellung davon und dieses enthaltende pharmazeutische Zusammensetzung.
DE3887068D1 (de) 2,2-Dimethylchromenderivate, Verfahren zur Herstellung und diese enthaltende pharmazeutische Zusammenstellungen.
ATA260590A (de) Glyzerinderivate, verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen